Can you use Wegovy to lose 20 pounds? What the evidence actually shows

Is losing 20 pounds on Wegovy a realistic expectation?

Twenty pounds is roughly 9 kg. Whether Wegovy gets you there depends largely on where you start. In the STEP 1 trial, published in the New England Journal of Medicine, adults treated with semaglutide 2.4 mg lost an average of around 15% of their body weight over 68 weeks. For someone starting at 80 kg, 15% is 12 kg, that is 26 pounds. For someone starting at 65 kg, the same percentage works out closer to 10 kg, so 20 pounds would represent their entire average loss and then some.

The headline is that 20 pounds is a modest target relative to what the trial data shows is possible. Many participants lost considerably more. That said, averages hide a spread: some people lose less, some far more. How quickly you reach the full 2.4 mg maintenance dose, whether you experience side effects that slow progression, and how well the lifestyle changes stick all play a role. A prescriber can help you set a realistic personal picture rather than working from population averages alone.

It is also worth knowing that the MHRA has now approved a higher 7.2 mg maintenance dose, with trial data showing around 20.7% average weight loss over 72 weeks, though the right dose for any individual is a clinical decision, not a preference. If you are wondering whether Wegovy is appropriate for a smaller goal like losing 10 pounds, that is a question worth exploring before you commit to treatment.

Does your BMI have to be a certain number to use Wegovy for weight loss?

Yes. Wegovy is licensed in the UK for adults with a BMI of 30 or above. If your BMI sits between 27 and 29.9, you can still qualify provided you have at least one weight-related health condition, high blood pressure, type 2 diabetes, high cholesterol, obstructive sleep apnoea or similar. If you want the specifics spelled out, our page on BMI requirements for Wegovy covers the detail.

One thing to flag: a BMI of 27 with 20 pounds to lose is a very different clinical picture from a BMI of 38 with 20 pounds to lose. Someone at the lower end of the eligibility range may have less body weight to draw on, so the same percentage loss translates to fewer pounds. That is not a reason to dismiss treatment (for people with weight-related conditions, even modest losses can significantly improve health markers) but it does affect how you frame the goal.

Lower BMI thresholds can apply for people of South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds under UK clinical guidance. If you are unsure how overweight you need to be to use Wegovy, the NHS BMI calculator is a practical starting point before you speak to a prescriber.

What happens in the real world, does Wegovy always reach the 15% figure?

Not always, and it is important to be straight about this. The 15% average from STEP 1 comes from a controlled trial setting with close monitoring, structured lifestyle support, and participants who completed the full course. Real-world results can differ. People who stop at a lower maintenance dose because of side effects, or who find the lifestyle adjustments harder to sustain, typically see smaller losses.

That is not a criticism of the medicine. It is a reason why clinical supervision matters throughout treatment, not just at the start. Our prescribers review each repeat order rather than simply renewing it, if progress has stalled or side effects are making the titration difficult, that is exactly the conversation to have before the next pen arrives. A question our prescribers hear most weeks is whether a slow first month means the medicine is not working; usually it means the dose has not yet reached therapeutic levels, because the starting dose is designed to give your digestive system time to adjust, not to drive weight loss from day one.

If 20 pounds is your target, the honest answer is that it is achievable for the majority of people who reach full maintenance dose and stay the course. If you are not yet certain whether you can use Wegovy given your personal circumstances, that is exactly what a clinical assessment is for. You can read more about the full eligibility picture for semaglutide before booking.

What else should you know before starting?

Wegovy is a prescription-only medicine. That means a prescriber assesses your medical history, current medicines and health conditions before anything is issued, not because the paperwork is bureaucratic, but because there are genuine contraindications. It is not recommended during pregnancy, breastfeeding, or if you are actively trying to conceive. It is not licensed for under-18s. People with a history of medullary thyroid carcinoma, pancreatitis or certain gastrointestinal conditions need a careful clinical conversation first.

Side effects are mostly gastrointestinal (nausea, loose stools, constipation, reflux) and are most noticeable when a dose increases, typically settling within a week or two. The slow titration schedule exists precisely to reduce how much of this you feel. If you experience severe, persistent abdominal pain that spreads to your back, seek medical attention promptly; the MHRA's guidance on GLP-1 medicines flags acute pancreatitis as an infrequent but serious possibility, detailed in their Drug Safety Update communications.

On cost: private treatment prices vary by provider and dose, and include a prescription and clinical oversight in any legitimate offering. Our page on where to buy Wegovy in the UK covers what to look for when choosing a provider. At nume, the price includes the consultation, prescription, and free next-working-day tracked delivery, no subscription, no hidden add-ons. The current treatment pricing is shown on our treatment page. If you are ready to find out whether Wegovy is clinically suitable for you, speak to our prescribers through a free consultation.